Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

Excerpt from the Press Release:

• Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic’s lead COVID-19 vaccine candidate.
• Dyadic’s lead COVID-19 Vaccine, DYAI-100, utilizes the SARS-CoV-2 Spike Protein receptor binding domain (RBD) and has been extensively studied in vitro and in vivo for its induction of high-titer neutralization activities in vaccinated animals against the SARS-CoV-2 virus and its major variants of concern (VoCs).
• MultiValent COVID-19 Vaccine is under development using the RBDs for the VoCs, such as delta, alpha, beta, gamma and lambda, and is designed to cover all known and emerging VoCs.

Click the button below to read the entire Press Release:

Continue Reading The Press Release